Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort

  • Cho, Hyo Jung; 
  • Kang, Seong Hee; 
  • Chon, Hye Yeon; 
  • Bae, SungA; 
  • Kim, Eunju; 
  • 외 10명
Citations

SCOPUS

0

초록

Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) shows marked sexual dimorphism, with estrogen believed to be liver-protective. This study investigated the independent association between circulating estradiol levels, MASLD, and advanced fibrosis (defined by fibrosis index-4 [FIB-4] ≥ 1.3) in Korean women, utilizing stratified analyses by age and body mass index (BMI) to identify context-dependent effects. Methods: We analyzed cross-sectional data from the Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry, including 995 women (352 with MASLD). Multivariable logistic regression was used to evaluate the association of log2-transformed estradiol with MASLD and high-risk fibrosis, stratified by age (proxy for menopausal status, ≥ 50 vs. < 50 years) and BMI (≥ 25 vs. < 25 kg/m2 ). Results: In multivariable analysis of the entire cohort, lower estradiol levels were independently associated with MASLD (adjusted odds ratio [aOR], 0.88; 95% confidence interval [CI], 0.79–0.98; P = 0.025). This association was particularly evident in women with lower BMI (aOR, 0.84; 95% CI, 0.71–0.98), but not in high BMI women, suggesting attenuation of estrogen’s metabolic protection in the presence of obesity. Estradiol demonstrated a strong and consistent inverse association with FIB-4 ≥ 1.3 (aOR, 0.65; 95% CI, 0.56–0.75; P < 0.001). This protective antifibrotic effect remained robust across BMI strata and was also significant in women aged ≥ 50 years (aOR, 0.70; 95% CI, 0.59–0.82; P < 0.001). Conclusion: Low circulating estradiol independently increases the risk of MASLD and highrisk fibrosis in women. While its protective effect against steatosis weakens with obesity, its antifibrotic effect remains strong across all subgroups. Estradiol may serve as an important hormonal marker for risk stratification in female MASLD patients. Trial Registration: ClinicalTrials.gov Identifier: NCT06843421

키워드

Estradiol; Liver Fibrosis; Metabolic Dysfunction-associated Steatotic Liver Disease; Risk Stratification; Women
제목
Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction–Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort
저자
Cho, Hyo Jung; Kang, Seong Hee; Chon, Hye Yeon; Bae, SungA; Kim, Eunju; Na, Seong Kyun; Kim, Su Jin; Kim, Dooyeon; Ahn, Hye Ri; Kim, Huigyeong; Cheong, Jae Youn; Baik, Soon Koo; Jung, Young Kul; Kim, Soon Sun; Yim, Hyung Joon
DOI
10.3346/JKMS.2026.41.E258
발행일
2026-11
유형
Article
저널명
Journal of Korean Medical Science
권
41
호
42
페이지
1 ~ 13

파일 다운로드

Thumbnail